Video

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.

Currently, CDK4/6 inhibitors are a standard first- or second-line treatment for patients with HR—positive, HER2-negative breast cancer, says Yardley.

Initially, there was a learning curve with the use of these agents, particularly for patients who have a high tumor burden or metastases in the liver or lung.

However, studies have demonstrated an improvement in overall response rates, progression-free survival, and overall survival with CDK4/6 inhibitors versus standard chemotherapy, says Yardley.

Moving forward, it will be important to understand resistance mechanisms and identify patients who are likely to respond to CDK4/6 inhibitors versus chemotherapy, concludes Yardley.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity